Corrections
When we get a fact wrong, we fix it on the page, date the fix there, and list it here: what was wrong, what the page says now, and every page it touched. Newest first.
Last correction How we correct
How corrections work
- We correct facts: a number, a price, a citation (a DOI or PubMed ID), a regulatory status, or a claim its source does not support.
- The fix is made on the page and dated there, and listed here. Supplement data changes are also logged on the updates page.
- A layout or wording change that leaves every fact as it was is not a correction, and is not listed.
- Found an error? Email contact@kymatalabs.com with the page address. Our editorial policy sets out how pages are sourced and checked.
Corrections log
PeterMD is listed again, with a conditional pass and a due-diligence note
PeterMD did not pass our vetting on Oct 8, 2026, and our pages named it only with that result: no price, score or link. We re-checked it on Oct 22, 2026 under our inclusion policy, which excludes a clinic only for clear deception or harm to customers. Its terms now name two pharmacies, and we found no report of an FDA warning letter naming it; Trustpilot still shows its profile removed, and it still names no prescribing clinician. It now has a conditional pass: it is priced and ranked in the testosterone comparison, but a conditional pass can never take Gold or our pick. Its review page lists what our due diligence found, and its links are paid links.
Live Vital’s GHK-Cu is an injection, and its page does not mention hair
Our hair loss page called Live Vital’s GHK-Cu a topical, said Live Vital lists hair thinning among its uses and that hair benefits typically take several months, and credited its GHK-Cu page with naming Dr. Patrick Taylor and HSA/FSA eligibility. That page, read on Oct 20, 2026, describes compounded GHK-Cu given by subcutaneous injection as a skin health protocol ($99/mo on a 10-week protocol, $297 total) and mentions none of those things. The page now says it is an injection, that Live Vital’s GHK-Cu page does not mention hair, and that a licensed clinician reviews the intake; HSA/FSA is now cited to Live Vital’s FAQ, and the row notes that Live Vital does not name its dispensing pharmacy on its site. The price is unchanged.
Clinics with no independent reviews no longer get a neutral reviews score
Our comparison rubric gave a clinic with no independent reviews at all the same neutral reviews score (62.5 of 100) as a 3.5-star rating, so a clinic nobody had reviewed could outscore one with a modest rating on a real review record. A clinic we checked and found with no Trustpilot reviews and no other review profile we could find now scores 37.5 on the reviews pillar, the midpoint of its scale (2.5 stars): below a neutral record, but above a clinic with many poor reviews. Its row and review page say “No independent reviews yet”. The reviews pillar is 20% of the score, so each of these clinics drops 5 points. GLP-1: MEDGm 75.5 (was 80.5), yourEra 75.5 (was 80.5), HealthRX 71.7 (was 76.7), Luvo Health 62.9 (was 67.9). Testosterone: ARSYNL Rx 78.8 (was 83.8). NAD+: HealthRX 70.7 (was 75.7), Luvo Health 64.4 (was 69.4). Sermorelin: HealthRX 69.6 (was 74.6), Luvo Health 64.4 (was 69.4). The same day we read the Trustpilot profiles we had not checked: SHED 4.6 stars from 1,141 reviews, now 75.4 for tirzepatide (was 70.1) and 75.2 for semaglutide (was 70.0); Embody 3.8 stars from 10,284 reviews, now 85.0 for NAD+ (was 83.5) and 85.8 for sermorelin (was 84.3). MEDGm’s vetting also became a conditional pass that day, and Gold needs a clean pass. GLP-1 medals are now Found Gold, Gala Silver and yourEra Bronze (were MEDGm Gold, yourEra Silver and Found Bronze), and Found is our GLP-1 pick (was MEDGm). In sermorelin, HealthRX no longer clears the medal bar for Bronze. Testosterone and NAD+ medals are unchanged.
28-day plans are now scored at their charge per month, the same way for every clinic
Plans billed every 28 days were not scored the same way for every clinic. Winona’s were scored at their charge per month, while Found’s and Luvo’s were scored on a slightly higher yearly total, which made them look a little more expensive in the price score. 28-day plans are now scored at their charge per month, the same way for every clinic, with an intro price counted as the first month. Found’s GLP-1 score is now 78.6 (was 78.0), Luvo’s is 67.9 for GLP-1 (was 67.2) and 69.4 for NAD+ and sermorelin (was 68.7), and Winona’s stays 83.9. No clinic’s medal or rank changed; in the GLP-1 comparison table, Found’s tirzepatide row moved up one place, above MEDGm’s tablets. Prices on the pages already showed the 28-day charge per month, with “billed every 28 days”.
Half-lives match the labels and the page; Mounjaro and Ozempic indications completed
Orforglipron’s half-life read “~11 hours” and its molecular weight “~400–500 Da”; the Foundayo label gives about 29 to 49 hours and 902.0 g/mol (orforglipron calcium). Tirzepatide now reads about 5 days and desmopressin tablets 1.5 to 2.5 hours, as their labels state. ARA 290’s glance read “~11 hours”; published data give about 2 minutes in plasma. Several meta descriptions printed a half-life their own page calls unpublished or unmeasured (PEG-MGF, MGF, thymosin beta-4, GLOW, KLOW, kyotorphin, N-acetyl Selank amidate, humanin); they no longer do. The tirzepatide page now names Mounjaro’s August 2026 indication to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk, and the semaglutide page Ozempic’s heart and kidney indications, from the labels.
Peptide mechanism summaries say what studies examined, not what a product does
The mechanism summaries that 78 peptide pages publish in their structured data, and that /peptides and the head-to-head pages show, described cell and animal findings as proven effects in people: for example that Endoluten “halts telomere degradation”, Retinalamin “reverses diabetic capillary dropout” and Chitomur “eliminates age-related urinary dysfunction”. Each now says what the compound is and what studies examined, in whom, and that most bioregulator work comes from one Russian research group. The Pentosan Polysulfate summary now gives its FDA-approved use and its retinal warning.
Cytomax and cytogen pages no longer give 10–30 day courses or injection doses
After correction “Cytomax pages quote the product label”, the Cytomax dosing tables still said “Courses of 10–30 days … as printed on the Cytomed label”, 38 bioregulator fact rows said “1-2× daily for 10-30 day cycles”, 11 cytogen FAQs said “typical 10–30 day courses”, the Khavinson stack tables gave 20–30 day courses, and several cytogen pages told readers to reconstitute or inject a research vial (Vesilute gave a 1–2 mg, about 10-day pattern). None of those course lengths is on the Vita-Stream label. The pages now quote the label serving where we read it (Endoluten, Cerluten, Visoluten, Suprefort, Ventfort, Gotratix, Pinealon, Vesugen) and otherwise say to see the product label, and they give no injection dose.
Comparison pages no longer call compounded listings “the same molecule”
The note under each group of providers on /telehealth/compare said “Same molecule; the gap is billing structure”, including for compounded semaglutide and tirzepatide, menopause visits, non-hormonal plans, NAD+ and sermorelin. Compounded drugs are not the FDA-approved product, and pharmacies, doses and visit scope differ. The note now says the listings share a name but formulation, dose, pharmacy or visit scope can differ. The page head now shows the latest date any row was checked.
Khavinson guide: Thymalin is a thymus extract, and the melatonin finding is attributed
The Khavinson bioregulator guide called Thymalin a Glu-Trp dipeptide “approved in Russia for immune restoration”; Thymalin is a thymus polypeptide extract registered as an immunomodulator, and Glu-Trp is Thymogen. It said Epithalon “restored” melatonin and that each bioregulator is “designed to restore youthful gene expression”; it now says night-time melatonin was higher after Epithalon in Khavinson-group studies of older people, and that the group proposes the peptides act on gene expression, mostly from cell and animal work. The Epitalon vs Thymalin comparison and the immune and injury protocols were reworded the same way.
Cytomax pages quote the product label instead of a “typical” 10–30 day course
The route notes on the Cytomax capsule pages said “typical Cytomed labeling” was 1–2 capsules daily in 10–30 day courses, repeated a few times a year, while the same pages quoted the Vita-Stream label (for Cerluten, “1-2 capsules, 1-2 times daily”). Each page now quotes the serving its Vita-Stream product page states, or says to see the product label where we have not read one; the course lengths are gone.
Failed-vetting review pages no longer show pros, a second Trustpilot figure or a neutral score
The Maximus review quoted the Trustpilot rating our vetting found (1.8 from 234 reviews) and, lower down, an older 4.4 in its pros and quick facts; the BrightMeds pros listed a 4.7 rating beside a vetting result built on one-star reviews; and the verdicts said “Scored neutral (5)” on pages marked “Not scored”. Review and head-to-head pages for clinics that failed our vetting now show no pros, no sentiment line and no rating other than the one in the vetting result, and their titles and descriptions no longer promise pricing or a score.
FAQ: compounded semaglutide is not “the same active ingredient”
The FAQ said compounded semaglutide “uses the same active ingredient” as Wegovy and Ozempic and is made by an FDA-registered 503B facility. FDA has cited that “same active ingredient” wording as false or misleading. The answer now says a compounded product carries the same ingredient name but is not the FDA-approved drug, that FDA does not review compounded drugs before they are marketed, and that some compounders have used salt forms FDA calls different active ingredients. The 503B sourcing claim is removed.
Study pages give vial strengths only, without syringe-unit math
After correction 17, the 23 study pages with a paid capsule link still showed “1 unit (U-100) = 50 mcg” in their reconstitution chapter, two showed a 100-unit insulin syringe table with a per-unit figure, and Epitalon’s route comparison described reconstituting a vial for subcutaneous use. The chapter now lists the vial strengths (mg per vial) and a plain calculator link, and the route comparison on these pages leaves out vial preparation.
Peptide summaries next to paid links no longer use hype or treatment claims
After correction 17, 31 more peptide summaries, shown as “previous/next” teasers next to paid links, still called compounds “radically effective”, “incredibly potent” or “an absolute biological shield” and claimed they reverse immunosuppression or eradicate fat tissue (Thymogen, Thymulin, Humanin, Adipotide, SLU-PP-332 and others). Each is now one factual sentence: what it is and what has been studied, in whom. Body text on the bioregulator and immune-protocol pages that said these peptides reverse thymic involution, reverse epigenetic aging of the vessel wall or speed recovery after a heart attack now says what the cell, animal and small Russian studies examined.
Hormone and GLP-1 regulatory notes corrected; the men’s TRT title no longer says “5 ranked”
Enclomiphene was shown as not on the WADA Prohibited List; it is the trans-isomer of clomifene and is prohibited (S4). Leuprorelin, triptorelin, gonadorelin and kisspeptin were filed under S4; WADA lists them under S2 (S2.2.1, LH-releasing factors, in men). The exenatide note implied Byetta is still sold; every US exenatide product is now listed as discontinued. Adlyxin was “no longer listed”; it was discontinued by Sanofi (2023). Thymosin alpha-1 read as FDA-approved on the immune protocol; it has FDA orphan-drug designation, not approval, and is approved in some countries outside the US. The men’s TRT page title said 5 clinics were ranked; it ranks 4 and lists 1, so it now says 5 compared. The Cerluten serving now quotes the Vita-Stream label everywhere.
Clinics that failed our vetting are no longer priced, scored or rated
Correction 13 said PeterMD, Maximus and BrightMeds were no longer priced anywhere, but the TRT comparison still listed their prices, the TRT cost page quoted a BrightMeds price, and their review pages showed full price tables, a checklist score, a “Best for” verdict and a review rating in the page markup. None of these pages prices, scores or rates them now; the review pages keep the dated vetting result.
Compounded semaglutide: not “the same active molecule” as Wegovy
After correction 11, one article still said compounded semaglutide and Wegovy contain the same active molecule. Wegovy contains semaglutide; compounded products are sold under the same ingredient name but are not the FDA-approved drug, and FDA calls the salt forms some compounders use (semaglutide sodium, semaglutide acetate) different active ingredients. The article now says so.
Bioregulator summaries no longer claim recovery from disease; study pages carry no injection handling
The one-line summaries of 38 bioregulators, shown as “previous/next” teasers next to paid links, described heart, thyroid, eye and bone-marrow recovery and disease reversal. Each is now one neutral sentence: what the product is and what its (mostly Russian) studies examined. Study pages with a paid capsule link also still showed a syringe-unit line, vial storage and degradation notes, and on Epitalon an after-mixing storage answer and a cycle recommendation; these are gone.
How it works: a syringe-unit example was off by a factor of five
The GLP-1 scheduler example said 0.5 mg of semaglutide from a 5 mg vial mixed with 2 mL is 4 units on a 100-unit syringe. At 2.5 mg/mL, 0.5 mg is 0.2 mL, which is 20 units; the example now says so. The calculators themselves were not affected.
GLP-1 trial figures and label doses checked against the sources
The GLP-1 guides gave tirzepatide’s SURMOUNT-1 result as −22.5% (the trial abstract reports −20.9% at 15 mg), called the trial figures placebo-adjusted (they are the drug group’s mean change), gave a week-by-week retatrutide phase 2 schedule that the trial’s published abstract does not give (one version also cited the wrong trial number), and listed 2.4 mg as the most Wegovy allows (its label now allows up to 7.2 mg). The guides now give the abstracts’ figures with PubMed IDs, the retatrutide trial arms and the phase 3 TRIUMPH-1 result, and the Wegovy label maximum.
Twelve FDA-approved drugs were labelled “research chemical”
Peptide pages without their own regulatory record fell back to “Not FDA-approved - research chemical”. That put the label on twelve FDA-approved drugs, among them bremelanotide (Vyleesi), dulaglutide (Trulicity), setmelanotide (Imcivree), pentosan polysulfate (Elmiron) and orforglipron, which FDA approved on April 1, 2026 as Foundayo. Every peptide page now has its own record, checked on Drugs@FDA, and a page without one would say its status is not yet recorded.
Thymosin alpha-1 is approved abroad, not by the FDA
Two posts said thymosin alpha-1 is “FDA-approved in 35+ countries”, and the side-effects guide listed it with semaglutide as FDA-approved. It is approved in more than 35 countries outside the US and is not FDA-approved; the posts now say so.
Bioregulator capsule pages no longer make disease claims
The 22 Cytomax capsule pages described courses for named diseases (prostate enlargement, COPD, macular degeneration, Hashimoto’s, pre-diabetes, high blood pressure, recovery after chemotherapy and others) next to a paid link. They now say what the products are, where the evidence comes from (mostly the developers’ own Russian studies) and that they are not intended to treat or prevent any disease, and give the label serving instead of disease courses.
Clinics that failed our vetting are no longer picked or priced anywhere
After correction 08, the men’s TRT page, the enclomiphene page, the TRT cost page, the cost calculator and three head-to-head pages still picked, priced or linked PeterMD, Maximus or BrightMeds, which failed our vetting. None of them does now; the three review pages say the clinic did not pass our vetting and why.
Comfrey: FDA advised removal in 2001; pregnancy caution added
The comfrey page said FDA “banned” oral comfrey, citing a secondary source, and that comfrey was banned in Germany. FDA’s July 6, 2001 letter told supplement makers that dietary supplements containing comfrey are adulterated and strongly recommended removing them; the page now cites it and no longer repeats the Germany line. It also adds the EU herbal monograph’s advice against use in pregnancy, and calls the knee trial’s product the ointment it was.
Compounded semaglutide is not the same drug as Ozempic or Wegovy
Two articles said compounded semaglutide is the same drug as Ozempic and Wegovy, uses the identical molecule and gives identical weight-loss results at the same dose; two guides to compounding pharmacies said the same. Compounded drugs are not FDA-approved, FDA does not review them for safety, effectiveness or quality, and FDA says the salt forms used in some of them are different active ingredients from the approved drugs. The first fix changed only the FAQ answers; the article text, a bioavailability table and the two guides’ FAQ answers were fixed later the same day. All four pages now say so in FDA’s words.
Embody: $99 a month after the first month, not $149
We priced Embody’s sermorelin and NAD+ injection plans at $149 a month after a $49 first month. Embody’s own pages say $49 for the first month, then $99 a month. The rankings and costs now use $99; Embody keeps first place in the NAD+ ranking on /telehealth/compare and on the sermorelin page.
A “research use only” label is not a legal shield
The guide said research peptides are legal to sell and buy in the US as long as they are not marketed for human use, and that the “research use only” label establishes this. FDA judges intended use from how a product is labeled, advertised and sold (21 CFR 201.128), not from the label alone. The paragraph now says so, and the same claim was fixed where it recurred: a comparison table cell and legal bullet, an FAQ answer and the bioregulator guide’s FAQ.
Sermorelin: only clinics that passed our vetting are ranked
The sermorelin page picked PeterMD, Maximus and BrightMeds by hand, although all three failed our vetting. Its picks, cost table and provider table now come from the official sermorelin ranking of vetted providers; the three are named only in a “did not pass our vetting” line, with no link, price or button. The peptide therapy page dropped them the same way, and its sermorelin price said “around $129 a month” where the lowest published price is $99.
Ipamorelin is not eligible for 503A compounding; sermorelin’s FDA history
Ipamorelin was nominated for 503A compounding and withdrawn, and it is not in Category 1 or on the bulks list, so a 503A pharmacy cannot compound it (it remains in Category 2 for 503B facilities). Its profile and the two blends that claimed pharmacy availability now say so. Sermorelin’s profile said its FDA approval was withdrawn; it now gives FDA’s finding that Geref was not withdrawn from sale for safety or effectiveness reasons.
Gala also sells brand-name Ozempic
Our GLP-1 pages said Gala sells compounded semaglutide and tirzepatide only. Gala now also sells brand-name Ozempic ($1,299 a month cash, with an insurance check) and lists the Wegovy pill as coming soon, per its site on October 19, 2026. Its rows now carry the brand-name option; no score, rank or medal changed.
No advice to combine a GLP-1 with research peptides
Several posts told readers to stack semaglutide or tirzepatide with research peptides or unapproved compounds. Those passages are gone: the stack posts now describe what is known, with FDA status, no doses and a line to talk to the prescriber. One citation was also wrong: the tesofensine trial (TIPO-1) is PMID 18950853, not 18978768, and its 10.6% weight loss was the 1.0 mg arm, not 0.5 mg.
Winona’s tablets, patches and capsules are FDA-approved
We listed Winona’s estrogen tablets, estrogen patch and progesterone capsules as compounded. Per Winona’s FAQ and product pages, those three are FDA-approved; only its creams are compounded, in its own 503A pharmacies. The provider line, cautions and FAQ answers now agree. Ranks and medals did not change.
Study design corrected on four evidence rows
Re-checking every flagged row against its PubMed abstract found four with the wrong design: magnesium chloride (depression, 2017) and alpha-lactalbumin (morning alertness, 2005) are crossover trials, and oxaloacetate (Alzheimer’s, 2021) and wheatgrass (chemotherapy, 2007) are open-label studies. Only the design changed; no grade, participant count, result or PubMed ID did.
Effect direction corrected on ten evidence rows
An audit found ten evidence rows whose effect direction did not match the study. They were corrected on six supplement pages, each with a dated entry in that page’s change log.
Dead DOIs and PubMed IDs replaced, and the text they supported
A link audit found five dead DOIs and two dead PubMed IDs. Each was replaced with the paper the sentence meant, and the text was corrected where the real paper says something else: the AOD-9604 guide credited a 12-week weight-loss trial to a 2001 paper that does not exist (it is now attributed to the developer’s trial as summarized in 2010, with the failed 24-week trial stated), the Wolverine stack guide said BPC-157 raises VEGF and FGF with a 4-hour half-life, which the cited review does not say, and a safety list said no lethal dose was ever found, where the review says only that toxicity “has not been reported”.
See also: Editorial policy · Supplement updates · Contact